Nobivac Myxo-RHD (live myxoma-vectoredrabbit-haemorrhagic-disease...) - QI08AD
Updated on site: 09-Feb-2018
|Medication name:||Nobivac Myxo-RHD|
|Substance:||live myxoma-vectoredrabbit-haemorrhagic-disease virus strain 009|
|Manufacturer:||Intervet International BV|
Live myxoma vectored RHD virus strain 009
This document is a summary of the European Public Assessment Report. Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendations on the conditions of use.
This document cannot replace a
What is Nobivac
What is Nobivac
How does Nobivac
How has Nobivac
Myxo-RHD been studied?
- Nobivac l4 - Intervet International BV
- Equilis strepe - Intervet International BV
- Nobivac bb - Intervet International BV
- Porcilis ar-t df - Intervet International BV
- Incurin - Intervet International BV
- Porcilis coliclos - Intervet International BV
Prescription drugs listed. Manufacturer: "Intervet International BV"
Fifteen field and laboratory studies were carried out, in which rabbits vaccinated with Nobivac Myxo- RHD were compared with unvaccinated rabbits to establish the onset and duration of immunity against myxoma and RHD viruses.
What benefit has Nobivac
Myxo-RHD shown during the studies?
The studies showed that Nobivac
What is the risk associated with Nobivac
A temporary increase in body temperature of
What is the withdrawal period?
The withdrawal period is the time allowed after administration of the medicine and before the animal can be slaughtered and the meat used for human consumption. The withdrawal period for Nobivac
Why has Nobivac
Myxo-RHD been approved?
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Nobivac
Other information about Nobivac
The European Commission granted a marketing authorisation valid throughout the European Union, for Nobivac
This summary was last updated on 7 September 2011.